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Lung Transplantation in Cystic Fibrosis:
Trends and Controversies
Joshua Blatter, MD, MPH, and Stuart Sweet, MD, PhD
This article is not an overview of all facets of lung transplantation in cystic fibrosis (CF), but rather it is intended
as a review of current allocation controversies, as well as of trends in diagnostics and management in lung
transplant recipients and in patients with end-stage lung disease. Despite changes in donor and recipient se-
lection, long-term survival in pediatric lung transplant has continued to be limited by chronic lung allograft
dysfunction (CLAD). Due to, in part, this short survival benefit, transplant continues to be an appropriate option
for only a subset of pediatric patients with CF. The feasibility of transplant as a therapeutic option is also affected
by the limited pediatric organ supply, which has moreover contributed to controversy over lung allocation.
Debates over the allocation of this scarce resource, however, may also help to drive innovation in the field of
lung transplant. Longer pretransplant survival—as aided by new lung bypass technologies, for example—could
help to alleviate organ shortages, as well as facilitate the transport of organs to suitable pediatric recipients.
Improved diagnosis and treatment for CLAD and for antibody-mediated rejection have the potential to extend
survival in pediatric lung transplant. Regardless, the relative rarity of transplant could pose future challenges for
pediatric lung transplant programs, which require adequate numbers of patients to maintain proper expertise.
Introduction
Over the first several decades of lung transplantation,common criteria for donor and recipient selection have
changed. While wait list time and geography were originally
used to pair donors and recipients, there is now an increased
focus on delivering pediatric organs to pediatric recipients,
and a complex scoring system (ie, the Lung Allocation Score
or LAS) is now being used for older pediatric patients. While
median survival has improved, the most significant survival
benefit has been noted in the first year following transplant,
with early postoperative survival improved by standardiza-
tion of surgical technique. Long-term survival, in contrast,
continues to be limited by chronic lung allograft dysfunction
(CLAD), which occurs in *50% of patients at 5 years fol-
lowing transplant.1 The limited expectations for graft sur-
vival mean that lung transplant is an appropriate option for
relatively few pediatric patients with cystic fibrosis (CF).
Moreover, lung transplant can be a realistic option for only
a very limited number of patients when so few quality organs
are available. A lack of organ supply continues to add to the
challenge of lung allocation. The allocation of pediatric lungs
has been adapted over time, with pediatric recipients being
prioritized for pediatric organs. Due to the lack of supply,
extending pretransplant survival is essential. Ex vivo lung
perfusion (EVLP), a technology that involves applying
therapy to lungs that have been removed from a deceased
donor, has the potential to improve the quality of marginal
donor lungs, thereby increasing organ supply. Extracorporeal
membrane oxygenation (ECMO) and paracorporeal lung as-
sist devices (PLAD), both variations on cardiopulmonary
bypass, have been used as bridges to lung transplant and have
the potential to sustain patients with end-stage lung disease
until suitable donor lungs can be found.2
Over time, improved CF therapeutics will sustain lung
function and may make lung transplant less necessary for
pediatric patients. Nevertheless, some children with CF
continue to present for lung transplant in the pediatric age
group. Moreover, if survival was improved, lung trans-
plantation could be of even greater potential utility to more
pediatric patients; better strategies to diagnose and treat
CLAD, for example, could make lung transplant a more
broadly beneficial intervention. Ongoing research directed at
identifying discrete phenotypes of chronic rejection may
improve both diagnosis and treatment. Antibody-mediated
rejection (AMR) likely has a role in CLAD, and clarity
regarding diagnosis and treatment may also improve long-
term survival in lung transplant. To improve survival in
pediatric lung transplantation, we will also need to under-
stand why there is a ‘‘high-risk window’’ in the late teenage
years, during which transplanted patients with CF have in-
creased mortality risk.3
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This review does not survey the entire process of lung
transplantation in CF, but rather highlights current trends in
the management of end-stage lung disease and of lung
transplant patients. An understanding of current manage-
ment in end-stage lung disease can help even nonspecialists
decide which patients are appropriate for referral, when it is
appropriate to refer them, and to where they might be re-
ferred. Lung transplantation profoundly challenges patients
with CF and their families, as well as clinicians and re-
searchers. Nevertheless, controversies in transplantation can
help to drive innovations in diagnosis and management of
disease in lung transplant patients and in patients with end-
stage lung disease.
History of Lung Allocation
Contemporary lung allocation involves the estimation of
transplant benefit. Transplant benefit is calculated based on
expected survival before transplant (pretransplant survival),
as well as the quality and duration of posttransplant survival.
The first formal policies governing lung allocation were
established in 1990. At that time, allocation depended onABO
compatibility and waiting list time, with organs preferentially
being offered to the local service area. In 1999, with in-
creasing concerns regarding wait list mortality, the Organ
Procurement and Transplantation Network (OPTN) estab-
lished a lung allocation subcommittee. The first subcommittee
proposal was presented in 2003, and the Lung Allocation
Committee proposed a revised lung allocation algorithm in
March 2004. The LAS was established for candidates aged
12 years and older, based on anticipated pretransplant and
posttransplant survival. Part of this proposal was the prefer-
ential allocation of pediatric lungs to pediatric recipients
(Table 1). The 12 years of age ‘‘breakpoint’’ was established
based on observed differences in diagnosis and survival pat-
terns between younger children and adolescents.4 In June
2004, the UNOS Board approved this revised lung allocation
algorithm, and on May 4, 2005, the lung allocation system
went live. The pediatric lung allocation policy was updated in
2010; among the changes made at that time were that donors
0–11 years of age were allowed access to organs across a
wider geographic area.
The Complexity of Pediatric Lung Allocation:
The Case of SM
The ongoing challenge of pediatric lung allocation is ef-
fectively highlighted in the case of SM.5 SM was a 10-year-
old female with CF, living in the Philadelphia area, who was
initially listed for transplant at the Children’s Hospital of
Philadelphia (CHOP) in December 2011. After she spent an
extended time on the wait list, the ‘‘height range’’ for ac-
ceptable organs was increased by her doctors in November
2012. This change could have enabled her to have access to
adult lungs for lobar transplant. SMwas admitted to CHOP in
February 2013 and transferred to the pediatric intensive care
unit for bilevel positive pressure ventilation in May 2013.
On May 23, 2013, CHOP requested an exception to allow
SM to have an LAS and to compete on the waiting list with
both adolescents and adults. The following day, SM’s
family made a public media appeal regarding her case. On
May 29–30, 2013, Secretary of Health and Human Services,
Kathleen Sebelius, requested information about pediatric
lung allocation and the OPTN responded. Secretary Sebelius
subsequently requested a prompt review of the pediatric
lung allocation policy. On June 5, 2013, SM’s family filed a
lawsuit and the Federal Judge, Michael Baylson, ordered the
OPTN to immediately cease the application of the Under 12
Rule in this case. Five days later, the OPTN Executive
Committee amended their policy, enacting the Lung Review
Board Exception Path, which allowed candidates aged 0–11
to be listed as adolescents. SM had a complicated course,
ultimately requiring 2 transplants and a prolonged postop-
erative hospital stay. On June 12, 2013, SM underwent her
first transplant, with a second transplant just 3 days later on
June 15, 2013. On August 26, 2013, SM was discharged
home. The temporary policy adopted in the SM case, al-
lowing for exceptions to the Under 12 Rule, was made
permanent in June 2014.
The Complexity of Allocation
The case of SM highlights some of the key challenges in
pediatric lung allocation. At the root of allocation problems
is the paucity of organs for pediatric lung transplant can-
didates aged 0–11 (Table 2). There are relatively few pe-
diatric donors and recipients, compared to adults. Only 2%
of wait list individuals are typically under 12 years old, and
2%–5% of individuals are from 12 to 18 years old. Never-
theless, there are also relatively few lung donors compared
to donors of other organs. Approximately, 5% of under
12-year-old donors provide lungs, while more than 35%
adolescent donors do (Fig. 1). This discrepancy represents a
potential opportunity to increase available lungs for chil-
dren, and improving the donor yield of young donors should
be a priority.
More than 90% of adolescent lung donor organs go to
adult recipients.6 This issue persists, despite the preferential
allocation of pediatric lungs to pediatric recipients (noted in
Table 1). Geography can be limiting, with suitable pediatric
recipients not always being available within a safe radius.
Allograft-sustaining therapies (such as EVLP, discussed
here) may enable the safe transport of organs over longer
distances. Expanding geographic allocation of pediatric or-
gans could help to ensure that pediatric organs are preferen-
tially offered to pediatric patients. Discrete age boundaries
between early childhood, adolescent, and adult recipients are
difficult to justify. There are not sufficient data, however, to
Table 1. Preferential Allocation of Pediatric Lungs to Pediatric Recipients
Priority Donor age <12 years Donor age 12–17 years Donor age 18 years and older
First Recipients <12 Recipients 12–17 Recipients 12 and older
Second Recipients 12–17 Recipients <12 Recipients <12
Third Recipients 18 and older Recipients 18 and older
Candidates <12 years old are prioritized by waiting time, and all others are prioritized by Lung Allocation Score.
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support the more widespread use of lobar transplant from
adult donors in pediatric recipients at this time.7
While the indications for lung transplantation have shif-
ted in the post-LAS era, the number of patients with CF who
receive transplants has remained generally stable. Since the
introduction of the LAS, a significantly increasing percent-
age of transplants have been done in patients with pulmo-
nary fibrosis (ie, Diagnosis Group D) and there has been a
relative decrease in the numbers of transplants in patients
with chronic obstructive pulmonary disease (ie, Diagnosis
Group A), not including CF (Fig. 2). Under the LAS system,
the waiting list mortality has decreased for adults with all
major end-stage lung disease diagnoses, including CF.8
The SM case also serves as a reminder that issues in
organ allocation, if left unresolved, have the potential to be
decided by nonmedical means. In the subsequent media
whirlwind, the SM case was tied to political disagreements
(such as those over the Affordable Care Act9) that do not
relate to the current organ allocation process. The outcome
of SM’s case was variously influenced by the news media,
by a social media campaign, by the Federal Judiciary, and
by the U.S. Cabinet. It is possible that future patients will
not be served equally by decisions shaped by such assorted
stimuli.
Management Trends and Challenges: CLAD
The initial focus in studies of chronic rejection was
bronchiolitis obliterans (BO), gradual destruction of small
airways by a presumed immune-mediated process.10 The
diagnosis of BO is complicated by the difficulty in estab-
lishing the diagnosis—typically by transbronchial or open
lung biopsy—and by the potential for sampling error, with a
‘‘clean’’ biopsy not guaranteeing that all parts of the lung
are unaffected by chronic rejection. Therefore, the Interna-
tional Society for Heart and Lung Transplantation (ISHLT)
established a clinical diagnosis of bronchiolitis obliterans
syndrome (BOS), reflecting irreversible declines in pulmo-
nary function testing (PFT).11 The definition of BOS has
undergone subsequent refinement, with the inclusion of
midexpiratory flow rate (FEF25–75) criteria, for example,
due to recognition of the potential for earlier detection of
airflow limitation.12
While BOS was traditionally associated with irreversible
airflow obstruction, alternate phenotypes of chronic rejec-
tion have become evident. Moreover, while BOS was tra-
ditionally identified as a clinical marker of BO, there is now
evidence that BOS is not specific for BO13 and that not all
chronic rejection is linked directly to observable pathologic
changes. With this expanding concept of ‘‘chronic rejec-
tion,’’ the more general term ‘‘chronic lung allograft dys-
function’’ (CLAD) has been adopted to describe sustained
declines in lung allograft function.
Instead of obstruction and air trapping, some patients with
CLAD develop interstitial infiltrates and restrictive patterns
on their PFT,14 and this clinical phenotype (‘‘restrictive al-
lograft syndrome’’ or RAS) has been associated with worse
prognosis. Phenotypes of chronic rejection are important
because they have the potential to determine prognosis, but
they may also have implications for treatment. Some patients
with CLAD are currently being defined by their response to
therapy, as in the proposed ‘‘azithromycin-responsive allo-
graft dysfunction’’ (ARAD), which is a form of CLAD de-
fined by forced expiratory volume in one-second (FEV1)
increase following the administration of azithromycin.15
Other proven potentially life-prolonging treatments for
CLAD are available, thereby reinforcing the importance of
phenotypic precision. A retrospective analysis identified a
decrease in the rate of FEV1 decline among patients receiving
extracorporeal photopheresis (ECP, which involves the irra-
diation and subsequent reinfusion of white blood cells),16 and
a prospective study showed evidence that a majority of
CLAD patients treated with ECP showed FEV1 stabiliza-
tion.17 Nevertheless, the optimal timing of ECP is not well
established, and it is evident that alternate CLAD phenotypes
such as RAS may have differing responses to ECP therapy.18
Management Trends and Challenges: AMR
The traditional definition of ‘‘antibody-mediated rejec-
tion’’ (AMR) involved a recipient’s preformed antibodies
contributing to a hyperacute response to human leukocyte
antigens (HLAs). ABO compatibility testing and cross-
matching have helped to make hyperacute rejection rela-
tively rare. Subsequent rejection was primarily identified as
cellular, a T-cell mediated process often resulting in peri-
vascular lymphocytic aggregation.
AMR is now more broadly understood as a variety of
interactions between preformed or de novo donor-specific
antibodies (DSAs) and lung allograft HLAs. This interaction
can trigger leukocyte recruitment or complement activation,
thereby leading to damage of the lung allograft. An AMR can
also develop in response to self-antigens (ie, autoantibodies),
such asK-alpha 1 tubulin and collagenV, and the development
Table 2. Contrast Between Number of Lung Offers Extended to Potential Recipients,
by Age, Sampled Between September 2010 and March 2013
Recipient
age (years)
REGs ever active REGs with at least 1 offer




N N (%) N (%) N (%)
0–5 54 29 (53.7) 27 (50.0) 26 (48.1)
6–11 49 34 (69.4) 29 (59.2) 18 (36.7)
12–17 115 100 (87.0) 88 (76.5) 62 (53.9)
18+ 7,323 6,826 (93.2) 6,262 (85.5) 4,396 (60.0)
Age was determined based on the maximum of age at listing or age at the start of the sampling period. A single patient listed at multiple
centers would have multiple REGs.39
REGs, registrations.
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of these antibodies is a risk factor for the development of
BOS.19 A National Institutes of Health (NIH) conference in
2003 developed staging criteria,20 from latent (stage I) to full
humoral rejection (stage IV). Latent humoral response is
defined as circulating DSAs in the absence of pathology
changes, complement deposition, or graft dysfunction, and it
is often left untreated.
Full humoral rejection (marked by DSAs, pathology
changes, complement deposition, and graft dysfunction) is
treated aggressively, usually with some combination of pulse
steroids, intravenous immunoglobulin (IVIG), and plasma-
pheresis, with consideration for other immunomodulatory
agents such as rituximab. Lower grade AMR, however, poses
several management challenges. Many laboratories report
mean fluorescence intensity (MFI), which represents the
amount of antibody bound relative to the amount of antigen
on a single bead in a DSA assay. This quantitative measure-
ment cannot be interpreted as a titer level,21 and the meaning
of a high or low MFI is still being debated.
Moreover, it is not clear whether high MFI DSAs should
be treated in the absence of complement fixation or asso-
ciated symptoms. DSAs have been associated with the de-
velopment of BOS,22,23 and overall survival is reduced in
patients who develop early DSAs after transplant.24 In a
prospective study of DSA treatment comparing IVIG alone
and IVIG plus rituximab, the latter group had significantly
improved survival.25 While current guidelines do not call for
preemptive treatment of latent AMR, there may be an on-
going trend toward more aggressive screening and treatment
of DSAs.
Patients who have reduced immune recognition of the lung
allograft may have improved transplant outcomes. Never-
theless, while minimal immune response can protect against
antibody formation and subsequent rejection, a complete
FIG. 2. Patterns of lung transplan-
tation, by Diagnosis Group, in the era
following implementationof theLung
Allocation Score. Diagnosis Group A
includes obstructive lung diseases
(such as chronic obstructive pulmo-
nary disease), Group B includes pul-
monary vascular disease, Group C
includes cystic fibrosis (and immune
deficiency), and Group D includes
restrictive lung diseases (such as idi-
opathic pulmonary fibrosis). In this
graph, each ‘‘year of transplant’’ starts
in May (eg, 2004 runs from May 4,
2004 to May 3, 2005).40
FIG. 1. Contrast between the per-
centage of under 12-year-old child
donors providing lungs each year,
compared to the percentage of ado-
lescent donors.40
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lack of immune response puts transplant patients at risk for
infection. One of the ultimate goals of studying AMR will be
to identify mechanisms of immune tolerance,26 a state in
which immunosuppression could be lessened because the
lung allograft would no longer be recognized as foreign.
Posttransplant survival, whether improved by earlier
detection or treatment of AMR or CLAD, is an exciting
opportunity in pediatric lung transplant. Pediatric lung
transplant recipients often have relatively little comorbidity
compared to adult patients, and interventions have the the-
oretical potential to extend allograft survival by decades.
New therapies are unlikely to be effective, however, if pa-
tients receive insufficient care, whether due to nonadherence
or to gaps in care associated with transition to adulthood.
Transplanted teenagers with CF have significantly increased
mortality,3 and identifying root causes of this ‘‘high-risk
window’’ will enable us to capitalize on our improving
understanding of lung transplantation.
Trends and Opportunities in Lung Transplant:
Bypass Technologies
One approach to issues of organ shortage is extending
pretransplant survival. The practice of transplant for pul-
monary arterial hypertension, for example, is being changed
by increasing availability of medical treatments, and it is
likewise possible that new CF therapeutics will enable us to
extend the period before transplant.
The unpredictability of waiting list times provides another
impetus to extending pretransplant survival. In a patient
with end-stage disease whose lungs can no longer provide
adequate gas exchange, ECMO can be used to remove and
oxygenate venous blood and then return it to either the ve-
nous or arterial circulation. ECMO is considered a relative
contraindication to lung transplant at some centers, but it has
also been evaluated as a possible ‘‘bridge’’ to transplant in
patients with end-stage lung disease. In a large retrospective
review of patients who underwent pretransplant ECMO,27
the ECMO patients were noted to have a significantly higher
LAS and to spend longer on cardiopulmonary bypass in-
traoperatively, but their survival was not different than those
control patients who were not on pretransplant ECMO.
Nevertheless, these patients were sustained on relatively
short runs of ECMO (with a median of 91 h).
‘‘Ambulatory ECMO’’ is a practice in which patients re-
ceive intensive physical rehabilitation during their ECMO run;
therefore, this bridge period is associated with less decondi-
tioning. Some authors suggest that ambulatory ECMO may be
easier to implement in patients with chronic respiratory in-
sufficiency (such as those with CF)—compared to those with
purely acute respiratory failure—as they have greater tolerance
for dyspnea and require less sedation.28 Patients on ambulatory
ECMOmay undergo tracheostomy to ensure airway protection
in case of ECMO failure and to allow for an increased pul-
monary toilet.29 The mean wait time to transplant in a series of
4 patients with CF using an ambulatory ECMO bridge was 8.5
days,30 a relatively short ECMO run. Long-term outcomes
from ambulatory ECMO patients will need to be studied, and
the feasibility of longer ambulatory ECMO runs may need to
be considered. An alternate bridging approach that has shown
promise is the use of a PLAD such as the Novalung oxy-
genator (Novalung GmbH, Heilbronn, Germany). PLAD in-
volve oxygenating blood from the pulmonary artery and
returning it to the left atrium, and this technology can be used
to wean a patient from ECMO support. Using PLAD, children
with ventilatory failure have been able to await suitable lung
donors for more than 2 months.31 PLAD may be simpler than
ECMO to implement, but while PLAD can be effective at
carbon dioxide removal, they have less utility in improving
oxygenation.32 Both ECMO and PLAD present challenges in
terms of vascular access and infection risk.
Nevertheless, rehabilitation while on lung bypass tech-
nology—likely easier in children with ECMO than with
PLAD—has the potential to improve pretransplant survival as
well as posttransplant outcomes.2 These measures are not
feasible in children who become ‘‘too sick,’’ however, and we
counsel possible early referral to a pediatric lung failure center
at which a variety of approaches, including bypass technolo-
gies and lung transplant, can be considered. There are also
ethical considerations in starting these technologies in patients
who may be lung transplant candidates; when a patient is
placed on ECMO, for example, as a bridge to transplant, there
is still a possibility that the patient will remain too sick for
transplant or that donor lungs will not become available. In
FIG. 3. Experience of pediatric
lung transplant centers, by year. The
last year in which International So-
ciety for Heart and Lung Transplan-
tation (ISHLT) has reported centers
performing 20 or more transplants
was 1998. In 2012, ISHLT reported
that no centers performed more than
9 transplants (ISHLT data, adapted
from Benden et al.41).
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such a case, there is a risk of the lung bypass technology
becoming a ‘‘bridge to nowhere.’’33 Any clinician discussing
lung bypass and transplant with families needs to emphasize
that lung transplant may not ultimately be feasible.
Trends and Opportunities in Lung
Transplant: EVLP
EVLP involves lung harvesting followed by ex vivo di-
agnostics and therapeutics. EVLP has the potential to alle-
viate some organ allocation issues by increasing organ
supply and by extending geographic areas for donation. One
of the most exciting aspects of EVLP involves the repair of
marginal organs, optimizing otherwise unusable lungs. High-
dose antibiotics can be added to lung perfusate, and empir-
ical antimicrobials in EVLP have already been shown to
significantly reduce bacterial load.34 EVLP can facilitate
ongoing evaluation of lung quality, including ex vivo bron-
choscopy and imaging studies.35 Perfusate also can be used
to evacuate pulmonary clots,36 thereby contributing to ex
vivo vascular reconditioning. Short-term outcomes in EVLP
have been similar to those in lung transplants without ex vivo
treatment, but EVLP may improve lung utilization.37 While
the potential to increase organ supply is promising, the
feasibility of EVLP in pediatric patients and long-term out-
comes in EVLP organ recipients will need to be explored.
The Future of Pediatric Lung
Transplantation for CF
While there will continue to be a need for pediatric lung
transplantation in congenital surfactant disorders, for exam-
ple, it is possible that both CF and pulmonary hypertension
will become less common as indications for pediatric lung
transplantation over time. If new molecular pharma-
cotherapies in CF (including potentiators such as ivacaftor)
help pediatric patients to sustain lung function, it is possible
that patients formerly transplanted during adolescence will
have no need for lung transplant until adulthood.
Diminishing numbers of pediatric lung transplants could
increase the complexity of an already challenging field.
Effective transplant teams are diverse, with staffing needs
for physicians, surgeons, nurse coordinators, nutritionists,
physical therapists, psychologists, social workers, financial
coordinators, child life professionals, and more. An adequate
number of transplants are required to sustain such a large
team, and it is therefore likely that there will continue to be a
limited number of pediatric lung transplant programs in the
United States. The number of transplant centers performing
10 or more pediatric lung transplants per year has decreased
across the world (Fig. 3). Centers with higher volumes of
pediatric lung transplants are noted to have better patient
survival statistics than low-volume centers, and pediatric
experience additionally contributes to improved lung trans-
plant outcomes in children.38 More pediatric-specific re-
search on topics such as extending pretransplant survival and
designing directed treatments for AMR and CLAD is needed.
Given that few pediatric patients will require lung transplant,
multicenter trials and collaboration with adult centers will be
used to fill our knowledge gaps.
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